It was observed that interleukin-13 (IL-13) loaded liposomes used against glioblastoma that had overexpression of IL-13 alpha2 receptors, resulted in a 5-fold reduction of tumor size as compared to free, non-targeted liposomes [9]. The gene discussed is IL13; the disease is glioblastoma.